Clinical Implication of UGT1A1 Promoter Polymorphism for Irinotecan Dose Escalation in Metastatic Colorectal Cancer Patients Treated with Bevacizumab Combined with FOLFIRI in the First-line Setting()()

PURPOSE: This study aimed to identify the efficacy and toxicity of the FOLFIRI regimen (fluorouracil, leucovorin, and irinotecan) with irinotecan dose escalation plus bevacizumab as first-line chemotherapy for metastatic colorectal cancer (mCRC) via UGT1A1 genotyping. METHODS: We administered bevaci...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Chien-Yu, Huang, Ching-Wen, Wu, I-Chen, Tsai, Hsiang-Lin, Ma, Cheng-Jen, Yeh, Yung-Sung, Chang, Se-Fen, Huang, Meng-Lin, Wang, Jaw-Yuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Neoplasia Press 2015
Materias:
Original article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700286/
https://www.ncbi.nlm.nih.gov/pubmed/26692528
http://dx.doi.org/10.1016/j.tranon.2015.11.002

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4700286/
https://www.ncbi.nlm.nih.gov/pubmed/26692528
http://dx.doi.org/10.1016/j.tranon.2015.11.002

Ejemplares similares